Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 672759, 10 pages
http://dx.doi.org/10.1155/2015/672759
Review Article

Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer

1Human Stem Cell Institute of the General Hospital, Ningxia Medical University, Yinchuan, Ningxia 750004, China
2Department of Thoracic Surgery of the General Hospital, Ningxia Medical University, Yinchuan, Ningxia 750004, China
3Center of Laboratory Medicine of the General Hospital, Ningxia Medical University, Yinchuan, Ningxia 750004, China
4Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong
5Key Laboratory of Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China, Ningxia University, Yinchuan, Ningxia 750021, China

Received 10 February 2015; Accepted 20 May 2015

Academic Editor: Martin Sebastian Staege

Copyright © 2015 Fei Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA: A Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Wang, G. Deng, X. Liu, and W. C. Cho, “Monoclonal antibodies in lung cancer,” Expert Opinion on Biological Therapy, vol. 13, no. 2, pp. 209–226, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. E. Larsen, T. Cascone, D. E. Gerber, J. V. Heymach, and J. D. Minna, “Targeted therapies for lung cancer: clinical experience and novel agents,” Cancer Journal, vol. 17, no. 6, pp. 512–527, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. S. Heist and D. Christiani, “EGFR-targeted therapies in lung cancer: predictors of response and toxicity,” Pharmacogenomics, vol. 10, no. 1, pp. 59–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Yoshida, G. Zhang, and E. B. Haura, “Targeting epidermal growth factor receptor: central signaling kinase in lung cancer,” Biochemical Pharmacology, vol. 80, no. 5, pp. 613–623, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. P. A. Jänne, J. A. Engelman, and B. E. Johnson, “Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology,” Journal of Clinical Oncology, vol. 23, no. 14, pp. 3227–3234, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Perez, T. Crombet, J. de Leon, and E. Moreno, “A view on EGFR-targeted therapies from the oncogene-addiction perspective,” Frontiers in Pharmacology, vol. 4, article 53, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Remon, T. Morán, M. Majem et al., “Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins,” Cancer Treatment Reviews, vol. 40, no. 1, pp. 93–101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. H. A. Yu, G. J. Riely, and C. M. Lovly, “Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors,” Clinical Cancer Research, vol. 20, no. 23, pp. 5898–5907, 2014. View at Publisher · View at Google Scholar
  10. Y. Lin, X. Wang, and H. Jin, “EGFR-TKI resistance in NSCLC patients: mechanisms and strategies,” The American Journal of Cancer Research, vol. 4, no. 5, pp. 411–435, 2014. View at Google Scholar
  11. M. Inui, G. Martello, and S. Piccolo, “MicroRNA control of signal transduction,” Nature Reviews Molecular Cell Biology, vol. 11, no. 4, pp. 252–263, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Hoshino and H. Matsubara, “MicroRNAs in cancer diagnosis and therapy: from bench to bedside,” Surgery Today, vol. 43, no. 5, pp. 467–478, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Wang, L. W. Chan, H. K. Law et al., “Exploring microRNA-mediated alteration of EGFR signaling pathway in non-small cell lung cancer using an mRNA:miRNA regression model supported by target prediction databases,” Genomics, vol. 104, no. 6, pp. 504–511, 2014. View at Publisher · View at Google Scholar
  14. D. N. Hayes and H. L. McLeod, “EGFR regulation by microRNA in lung cancer: a rose by any other name ... is an increasingly complicated rose,” Annals of Oncology, vol. 19, no. 6, pp. 1036–1037, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. G. J. Weiss, L. T. Bemis, E. Nakajima et al., “EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines,” Annals of Oncology, vol. 19, no. 6, pp. 1053–1059, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. G. G. Gomez, J. Wykosky, C. Zanca, F. B. Furnari, and W. K. Cavenee, “Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks,” Cancer Biology and Medicine, vol. 10, no. 4, pp. 192–205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. R. M. Mader, S. Foerster, N. Sarin et al., “NSCLC cells adapted to EGFR inhibition accumulate EGFR interacting proteins and down-regulate microRNA related to epithelial-mesenchymal transition,” International Journal of Clinical Pharmacology and Therapertics, vol. 52, no. 1, pp. 92–94, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. L. W. C. Chan, F. F. Wang, and W. C. S. Cho, “Genomic sequence analysis of EGFR regulation by microRNAs in lung cancer,” Current Topics in Medicinal Chemistry, vol. 12, no. 8, pp. 920–926, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Kefas, J. Godlewski, L. Comeau et al., “microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma,” Cancer Research, vol. 68, no. 10, pp. 3566–3572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. R. J. Webster, K. M. Giles, K. J. Price, P. M. Zhang, J. S. Mattick, and P. J. Leedman, “Regulation of epidermal growth factor receptor signaling in human cancer cells by MicroRNA-7,” The Journal of Biological Chemistry, vol. 284, no. 9, pp. 5731–5741, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-T. Chou, H.-H. Lin, Y.-C. Lien et al., “EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF,” Cancer Research, vol. 70, no. 21, pp. 8822–8831, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. M. Bjaanaes, A. R. Halvorsen, S. Solberg et al., “Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas,” International Journal of Cancer, vol. 135, no. 8, pp. 1812–1821, 2014. View at Publisher · View at Google Scholar
  23. S. Dacic, L. Kelly, Y. Shuai, and M. N. Nikiforova, “miRNA expression profiling of lung adenocarcinomas: correlation with mutational status,” Modern Pathology, vol. 23, no. 12, pp. 1577–1582, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Yamaguchi, M. Takanashi, M. Tanaka et al., “Isolation of miRNAs that target EGFR mRNA in human lung cancer,” Biochemical and Biophysical Research Communications, vol. 420, no. 2, pp. 411–416, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. L.-K. Wang, T.-H. Hsiao, T.-M. Hong et al., “MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma,” PLoS ONE, vol. 9, no. 5, Article ID e96765, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Seike, A. Goto, T. Okano et al., “miR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 29, pp. 12085–12090, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. H. Guo, C. Zhang, J. Shi et al., “Abnormal activation of the EGFR signaling pathway mediates the downregulation of miR-145 through the ERK1/2 in non-small cell lung cancer,” Oncology Reports, vol. 31, no. 4, pp. 1940–1946, 2014. View at Publisher · View at Google Scholar
  28. Y.-L. Wu, C. Zhou, C.-P. Hu et al., “Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 15, no. 2, pp. 213–222, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. K.-Y. Su, H.-Y. Chen, K.-C. Li et al., “Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 30, no. 4, pp. 433–440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Shen, D. Tang, R. Yao et al., “MicroRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation,” Medical Oncology, vol. 30, no. 4, article 750, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. W. C. S. Cho, A. S. C. Chow, and J. S. K. Au, “MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1,” RNA Biology, vol. 8, no. 1, pp. 125–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Garofalo, G. Romano, G. Di Leva et al., “EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers,” Nature Medicine, vol. 18, no. 1, pp. 74–82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Li, S. Ren, X. Li et al., “MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer,” Lung Cancer, vol. 83, no. 2, pp. 146–153, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Zhang, Y. Su, F. Xu, J. Kong, H. Yu, and B. Qian, “Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers,” PLoS ONE, vol. 8, no. 11, Article ID e81408, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Xu, H. Zhang, Y. Su, J. Kong, H. Yu, and B. Qian, “Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers,” Clinical and Translational Oncology, vol. 16, no. 11, pp. 980–985, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Acunzo, G. Romano, D. Palmieri et al., “Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 21, pp. 8573–8578, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Wang, B. Cheng, L. Miao, Y. Me, and M. Wu, “Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression,” Cell Death and Disease, vol. 4, no. 4, article e574, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Mudduluru, P. Ceppi, R. Kumarswamy, G. V. Scagliotti, M. Papotti, and H. Allgayer, “Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer,” Oncogene, vol. 30, no. 25, pp. 2888–2899, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Liu, X. Shao, W. Gao et al., “MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor,” The FEBS Journal, vol. 279, no. 20, pp. 3800–3812, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Chen, I. A. Umelo, S. Lv et al., “miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells,” PLoS ONE, vol. 8, no. 3, Article ID e60317, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Xu, N. Wang, X. Wang et al., “miR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer,” Prostate, vol. 72, no. 11, pp. 1171–1178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Katakowski, X. Zheng, F. Jiang, T. Rogers, A. Szalad, and M. Chopp, “MiR-146b-5p suppresses EGFR expression and reduces In Vitro migration and invasion of glioma,” Cancer Investigation, vol. 28, no. 10, pp. 1024–1030, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Adam, M. Zhong, W. Choi et al., “miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy,” Clinical Cancer Research, vol. 15, no. 16, pp. 5060–5072, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. Z. Zhang, Z.-B. Liu, W.-M. Ren, X.-G. Ye, and Y.-Y. Zhang, “The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells,” International Journal of Molecular Medicine, vol. 30, no. 4, pp. 856–862, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Mataki, N. Seki, T. Chiyomaru et al., “Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma,” International Journal of Oncology, vol. 46, no. 3, pp. 1039–1050, 2015. View at Publisher · View at Google Scholar
  46. X. Zhou, Y. Ren, L. Moore et al., “Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status,” Laboratory Investigation, vol. 90, no. 2, pp. 144–155, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. W. W. Du, L. Fang, M. Li et al., “MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling,” Journal of Cell Science, vol. 126, no. 6, pp. 1440–1453, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Salim, N. S. Akbar, D. Zong et al., “MiRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence,” British Journal of Cancer, vol. 107, no. 8, pp. 1361–1373, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Kitamura, M. Seike, T. Okano et al., “MiR-134/487b/655 cluster regulates TGF-β-induced epithelial- mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells,” Molecular Cancer Therapeutics, vol. 13, no. 2, pp. 444–453, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. Y.-F. Gu, H. Zhang, D. Su et al., “miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer,” Chinese Medical Journal, vol. 126, no. 23, pp. 4435–4439, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Zhou, X. Chen, J. Zhao, Z. Bao, P. Zhang, and Z. Liu, “MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET,” Cancer Letters, vol. 351, no. 2, pp. 265–271, 2014. View at Publisher · View at Google Scholar
  52. A. Ahmad, M. Y. Maitah, K. R. Ginnebaugh et al., “Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs,” Journal of Hematology and Oncology, vol. 6, no. 1, article 77, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Gao, X. Fan, W. Li, W. Ping, Y. Deng, and X. Fu, “MiR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124,” Biochemical and Biophysical Research Communications, vol. 446, no. 1, pp. 179–186, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Zhong, X. Ma, C. Sun, and L. Chen, “MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer,” Chemico-Biological Interactions, vol. 184, no. 3, pp. 431–438, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. C. G. Lee, S. McCarthy, M. Gruidl, C. Timme, and T. J. Yeatman, “MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance,” PLoS ONE, vol. 9, no. 1, Article ID e84597, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. J. L. Bryant, J. Britson, J. M. Balko et al., “A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,” British Journal of Cancer, vol. 106, no. 1, pp. 148–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Izumchenko, X. Chang, C. Michailidi et al., “The TGFbeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors,” Cancer Research, vol. 74, no. 14, pp. 3995–4005, 2014. View at Publisher · View at Google Scholar
  58. Y. Wang, H. Xia, Z. Zhuang, L. Miao, X. Chen, and H. Cai, “Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer,” Cell Death & Disease, vol. 5, no. 5, Article ID e1227, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Rai, N. Takigawa, S. Ito et al., “Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells,” Molecular Cancer Therapeutics, vol. 10, no. 9, pp. 1720–1727, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Li, Y. Zheng, G. Sun, and S. Xiong, “Restoration of miR-7 expression suppresses the growth of Lewis lung cancer cells by modulating epidermal growth factor receptor signaling,” Oncology Reports, vol. 32, no. 6, pp. 2511–2516, 2014. View at Publisher · View at Google Scholar
  61. H.-S. Jeon, Y. H. Lee, S. Y. Lee et al., “A common polymorphism in pre-microRNA-146a is associated with lung cancer risk in a Korean population,” Gene, vol. 534, no. 1, pp. 66–71, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. J. A. Engelman, K. Zejnullahu, T. Mitsudomi et al., “MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling,” Science, vol. 316, no. 5827, pp. 1039–1043, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Garofalo and C. M. Croce, “MicroRNAs: master regulators as potential therapeutics in cancer,” Annual Review of Pharmacology and Toxicology, vol. 51, pp. 25–43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. K. Politi, P.-D. Fan, R. Shen, M. Zakowski, and H. Varmus, “Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma,” Disease Models & Mechanisms, vol. 3, no. 1-2, pp. 111–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. V. Del Vescovo, M. Grasso, M. Barbareschi, and M. A. Denti, “MicroRNAs as lung cancer biomarkers,” World Journal of Clinical Oncology, vol. 5, no. 4, pp. 604–620, 2014. View at Publisher · View at Google Scholar
  66. I. S. Donev, W. Wang, T. Yamada et al., “Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer,” Clinical Cancer Research, vol. 17, no. 8, pp. 2260–2269, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Cufí, R. Bonavia, A. Vazquez-Martin et al., “Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo,” Scientific Reports, vol. 3, article 2459, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. Z. Zhang, J. C. Lee, L. Lin et al., “Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer,” Nature Genetics, vol. 44, no. 8, pp. 852–860, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. W. C. S. Cho, “Targeting signaling pathways in lung cancer therapy,” Expert Opinion on Therapeutic Targets, vol. 17, no. 2, pp. 107–111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. W. C. S. Cho, “MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy,” International Journal of Biochemistry and Cell Biology, vol. 42, no. 8, pp. 1273–1281, 2010. View at Publisher · View at Google Scholar · View at Scopus